PO-1793: BioXmark liquid fiducials to enable radiotherapy tumor boosting in rectal cancer feasibility trial. (November 2020) - Berbée, M.; Opbroek, T.; Paulissen, J.; Houben, R.; Van Limbergen, E.; Ta, B.; Steenbakkers, I.; Verhaegen, F.; De Ridder, R.; Jansen, R.; Melenhorst, J.; Bakers, F.; et al.